0000950170-24-030482.txt : 20240312 0000950170-24-030482.hdr.sgml : 20240312 20240312215740 ACCESSION NUMBER: 0000950170-24-030482 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scalzo Richard William CENTRAL INDEX KEY: 0001789545 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24744481 MAIL ADDRESS: STREET 1: 25 ALBERTA LANE CITY: HOLLISTON STATE: MA ZIP: 01746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-03-08 0001818794 Dyne Therapeutics, Inc. DYN 0001789545 Scalzo Richard William 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false SVP, Head of Finance & Admin. true Common Stock 2024-03-08 4 M false 68919 5.54 A 190874 D Common Stock 2024-03-08 4 M false 17333 5.54 A 208207 D Common Stock 2024-03-08 4 S false 30755 25.31 D 177452 D Common Stock 2024-03-08 4 S false 55208 26.72 D 122244 D Common Stock 2024-03-08 4 S false 289 27.33 D 121955 D Common Stock 2024-03-11 4 S false 1082 25.70 D 120873 D Common Stock 2024-03-11 4 S false 1590 24.99 D 119283 D Stock option (right to buy) 5.54 2024-03-08 4 M false 68919 0 D 2030-07-30 Common Stock 68919 9855 D Stock option (right to buy) 5.54 2024-03-08 4 M false 17333 0 D 2030-07-30 Common Stock 17333 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive. Includes 115,624 unvested RSUs. The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020. The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. /s/ Richard Scalzo 2024-03-12